Literature DB >> 28621113

Alteration of DNA Methylation in Gastric Cancer with Chemotherapy.

Su Jin Choi1, Seok Won Jung1, Sora Huh1, Yoon-Seok Chung2, Hyosun Cho3, Hyojeung Kang1.   

Abstract

Epigenetic alterations such as DNA methylation, histone acetylation, and chromatin remodeling can control gene expression by regulating gene transcription. DNA methylation is one of the frequent epigenetic events that play important roles in cancer development. Cancer cells can gain significant resistance to anticancer drugs and escape programmed cell death through major epigenetic changes, including DNA methylation. To date, several research groups have identified instances of both (i) hypermethylation of tumor suppressor genes, and (ii) global hypomethylation of oncogenes. These changes in DNA methylation status could be used as biomarkers for the diagnosis and prognosis of cancer patients undergoing chemotherapies or other clinical therapies. Herein, we describe genes for which methylation is dependent upon anticancer drug resistance in patients with gastric cancer; we then suggest a significant epigenetic target to focus on for overcoming anticancer drug resistance.

Entities:  

Keywords:  5-FU; DNA methylation; chemoresistance; cisplatin; gastric cancer

Mesh:

Year:  2017        PMID: 28621113     DOI: 10.4014/jmb.1704.04035

Source DB:  PubMed          Journal:  J Microbiol Biotechnol        ISSN: 1017-7825            Impact factor:   2.351


  26 in total

1.  Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival.

Authors:  David H Murray; Erin L Symonds; Graeme P Young; Susan Byrne; Philippa Rabbitt; Amitesh Roy; Kathryn Cornthwaite; Christos S Karapetis; Susanne K Pedersen
Journal:  J Cancer Res Clin Oncol       Date:  2018-07-10       Impact factor: 4.553

Review 2.  The FOXO family of transcription factors: key molecular players in gastric cancer.

Authors:  Ying Liu; Xiang Ao; Yi Jia; Xiaoge Li; Yu Wang; Jianxun Wang
Journal:  J Mol Med (Berl)       Date:  2022-06-10       Impact factor: 5.606

Review 3.  Epigenetic Therapeutics Targeting NRF2/KEAP1 Signaling in Cancer Oxidative Stress.

Authors:  Shunhao Zhang; Sining Duan; Zhuojun Xie; Wanlin Bao; Bo Xu; Wenbin Yang; Lingyun Zhou
Journal:  Front Pharmacol       Date:  2022-06-09       Impact factor: 5.988

Review 4.  Role of transcribed ultraconserved regions in gastric cancer and therapeutic perspectives.

Authors:  Shen-Shuo Gao; Zhi-Kai Zhang; Xu-Bin Wang; Yan Ma; Guo-Qing Yin; Xiao-Bo Guo
Journal:  World J Gastroenterol       Date:  2022-07-07       Impact factor: 5.374

5.  MiR-874-3p represses the migration and invasion yet promotes the apoptosis and cisplatin sensitivity via being sponged by long intergenic non-coding RNA 00922 (LINC00922) and targeting Glycerophosphodiester Phosphodiesterase Domain Containing 5 (GDPD5) in gastric cancer cells.

Authors:  Xiaoyu Zhang; Xudong Dai; Xin Zhao; Jian Wang; Jin Dou; Haiwen Zhuang; Ning Chen; Haijian Zhao
Journal:  Bioengineered       Date:  2022-03       Impact factor: 6.832

6.  A methylation-based mRNA signature predicts survival in patients with gastric cancer.

Authors:  Yang Li; Rongrong Sun; Youwei Zhang; Yuan Yuan; Yufeng Miao
Journal:  Cancer Cell Int       Date:  2020-07-06       Impact factor: 5.722

7.  An Analysis Regarding the Association Between the ISLR Gene and Gastric Carcinogenesis.

Authors:  Shu Li; Wei Zhao; Manyi Sun
Journal:  Front Genet       Date:  2020-06-16       Impact factor: 4.599

8.  Long non-coding RNA TPTEP1 inhibits hepatocellular carcinoma progression by suppressing STAT3 phosphorylation.

Authors:  Hongda Ding; Junpeng Liu; Ruoyao Zou; Pengrui Cheng; Yang Su
Journal:  J Exp Clin Cancer Res       Date:  2019-05-09

Review 9.  DNA methylation in human diseases.

Authors:  Zelin Jin; Yun Liu
Journal:  Genes Dis       Date:  2018-01-31

Review 10.  Significant function and research progress of biomarkers in gastric cancer.

Authors:  Dong Mei Ye; Gaosheng Xu; Wei Ma; Yuxuan Li; Weiru Luo; Yiyang Xiao; Yong Liu; Zhiwei Zhang
Journal:  Oncol Lett       Date:  2019-11-11       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.